Original news and analysis on international IP policy
The role of intellectual property in a wide range of public health challenges - access to medicines, vaccine prices, procurement strategies, and research for diseases of the poor - is a focal point in 2013 cutting across national, regional, and international policymaking.
European talks aimed at dragging copyright law into the digital age are not likely to produce results any time soon because of resistance from rights holders and political manoeuvring in the European Commission, players from the internet service provider and consumer sectors say. But the Commission said while it's true that changes could take several years, there will be regulation if needed.
The major recording industry association has released its annual report for 2012, announcing a 9 per cent increase in revenues from digital sales of music, with licensed music services on the rise. It also said it benefits most in countries where internet service providers have worked to drive down use of unauthorised music download sites.
After months of delay, the Standing Committee of the Law of Patents (SCP) opened a meeting on 25 February at the World Intellectual Property Organization and will endeavour to advance negotiations on highly contentious issues including quality of patents, patents and health, and exceptions and limitations to patent rights.
It has become routine for companies to outsource many business functions. Human resources, customer service, accounting, manufacturing of components - all have been outsourced. Now, however, a growing number of US businesses are outsourcing something new: patent licensing. And this outsourcing may hurt both the US economy and its patent system.
As several countries prepare to sign an international agreement establishing an EU unified patent court, debate still rages over whether the concept of the court, and of a single EU patent, is actually feasible. Some say a unified patent in the near term is a “dead letter,” while one patent lawyer believes that while some technical issues remain, the system will spring into life in the not-too-distant future.
Alongside the World Intellectual Property Organization meeting on protection of genetic resources last week, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) organised a side event on natural product research.
The coming year promises to be very interesting at the intersection of intellectual property with biotechnology and biodiversity. Patentability of human genes in the United States, of conventionally bred plants in Europe, plant breeders' rights and the management of regulatory authorisations when patents on genetic traits expire, the future of genetically modified organisms in developing countries, and the usual resistance they are meeting from civil society and famers' groups are some of the issues that will continue to feed debates – and potentially create opportunities - in 2013.
Global food security lies in the capacity to access and contribute to a wide pool of genetic material, the chair of the United Nations treaty on plant genetic material said on the margin of this week’s World Intellectual Property Organization meeting on the protection of genetic resources. But the origin of this genetic material is often impossible to determine, particularly for crops, the treaty secretary said.
From changes in policymaking leadership and staffing shake-ups to a flurry of hiring in law firms and new strategic alliances, the past few months have been an interesting time for IP people watching. With over 40 news items and over 80 names, here’s a substantial update on who’s who across governments, nonprofit organisations, and the private sector.
The first revision of what could become an international instrument on the protection of genetic resources was issued this morning and submitted for comments from World Intellectual Property Organization delegates.
A number of patents on genetically modified organisms (GMOs) in agriculture will expire in the coming years and this could be a problem for the biotechnology industry in terms of regulatory authorisations. A private sector initiative has recently been launched to address the issue.